Peroxiredoxin-2 represses NRAS-mutated melanoma cells invasion by modulating EMT markers.
Biomed Pharmacother
; 177: 116953, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-38955087
ABSTRACT
The second most common mutation in melanoma occurs in NRAS oncogene, being a more aggressive disease that has no effective approved treatment. Besides, cellular plasticity limits better outcomes of the advanced and therapy-resistant patients. Peroxiredoxins (PRDXs) control cellular processes through direct hydrogen peroxide oxidation or by redox-relaying processes. Here, we demonstrated that PRDX2 could act as a modulator of multiple EMT markers in NRAS-mutated melanomas. PRDX2 knockdown lead to phenotypic changes towards invasion in human reconstructed skin and the treatment with a PRDX mimetic (gliotoxin), decreased migration in PRDX2-deficient cells. We also confirmed the favorable clinical outcome of patients expressing PRDX2 in a large primary melanoma cohort. This study contributes to our knowledge about genes involved in phenotype switching and opens a new perspective for PRDX2 as a biomarker and target in NRAS-mutated melanomas.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Peroxiredoxins
/
Epithelial-Mesenchymal Transition
/
GTP Phosphohydrolases
/
Melanoma
/
Membrane Proteins
/
Mutation
/
Neoplasm Invasiveness
Limits:
Female
/
Humans
Language:
En
Journal:
Biomed Pharmacother
Year:
2024
Document type:
Article
Country of publication:
Francia